1. Scrip
  2. >>New Products

Stockwatch: Intercepting The Falling Knives Of NASH

Misperceptions Of Safety And Efficacy Plus The Invalidation Of A Surrogate Marker Hit Intercept

 
• By Andy Smith

A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.

StockWatch_Andy-Smith_V1_1200.jpg
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

On the Sunday night before the 2014 J.P. Morgan Healthcare conference, Intercept Pharmaceuticals, Inc.was the talk of the town in the bars around San Francisco. This was because of its recently announced positive results for obeticholic acid (OCA) in non-alcoholic steatohepatitis (NASH). Six years later, the FDA issued a complete response letter (CRL) for OCA in NASH amid consternation on OCA’s safety, efficacy, surrogate endpoints and the real number of NASH patients.

That 2014 J.P. Morgan conference was Intercept’s coming-out party. The announcement of the positive results from an interim analysis of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

Pipeline Watch: Eleven Approvals And ADA Readouts Dominate

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Empty Promises: Five Drugs That Fell Short Of Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets underperform their pre-launch sales predictions, which can be disastrous to their developers and marketers. In this article, Scrip highlights several historic examples and the factors that influenced their poorer-than-expected performance.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.